Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06163534 · ClinicalTrials.gov registry record
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
A clinical trial of Head and Neck Squamous Cell Carcinoma, sponsored by Tempus AI.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT06163534 is a study of Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 500 participants, above the 113-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (342% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06163534, a study of Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Conditions Studied
Study Locations (20)
California
- City of Hope - Duarte
- USC/Norris Comprehensive Cancer Center - Los Angeles
- University of California, Los Angeles - Los Angeles
- Stanford - Palo Alto
- Providence Medical Foundation - Santa Rosa
Georgia
- Morehouse - Atlanta
- Piedmont Healthcare - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- Cancer Care Specialists of Illinois - Decatur
- Illinois Cancer Care - Peoria
Missouri
- Oncology Hematology Associates - Springfield
- Washington University in St. Louis - St Louis
Kansas
- University of Kansas - Westwood
Maryland
- University of Maryland - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2028-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06163534
The ClinicalTrials.gov registry entry for NCT06163534 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 113-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (342% higher). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT06163534 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06163534 about?
NCT06163534 is a clinical study titled "A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)". The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
What is the current status of trial NCT06163534?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-08-01. Estimated completion is 2028-03-01.
What conditions does trial NCT06163534 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma.
Who is sponsoring clinical trial NCT06163534?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06163534 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
3D Specimen Maps for RT Planning
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.